Piper Sandler analyst Edward Tenthoff downgraded iTeos Therapeutics (ITOS) to Neutral from Overweight with a price target of $10.05, down from $12, after the company entered into am merger agreement whereby Concentra Biosciences will acquire iTeos for $10.047 in cash per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- Vor Bio appoints Cumbo, Detheux to board of directors
- iTeos Therapeutics Announces Merger with Concentra Biosciences
- iTeos to be acquired by Concentra for $10.047 per share in cash plus CVR
- GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment
- GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab